- ByStartupStory | February 23, 2024
US-based Aptar Digital Health, a unit of AptarGroup, Inc., has acquired Singapore-based Healint, known for virtual clinical studies and patient registry. The acquisition aligns with Aptar Digital’s strategy to broaden its portfolio in neurology. “With Healint, we now have the in-house expertise to cover the entire lifecycle of a drug,” said Sai Shankar, President of Aptar Digital Health.
Healint’s ability to conduct global clinical studies complements Aptar Digital’s solutions. The details of the deal remain undisclosed. The integration of Healint into Aptar Digital’s operations will commence immediately. François Cadiou, CEO and Founder of Healint, stated, “This acquisition will accelerate the development of our AI-powered precision medicine SaMD.”
Founded in 2013, Healint provides clinically validated data collection using self-input and sensor data. It generates real-world evidence for patients, physicians, and researchers to improve treatment outcomes. Aptar Digital plans to scale up Healint’s platform to adjacent therapeutic indications in neurology and immunology.
Healint’s patented migraine mobile app, Migraine Buddy, has over three million users. Aptar Digital provides digital patient support programs and disease management solutions. The startup’s expertise in AI-powered precision medicine SaMD will enhance Aptar Digital’s offerings.
The expanded capabilities include patient community management, patient activation, and digital diagnostics. Aptar Digital aims to strengthen its global footprint for digital health deployment. “This acquisition will accelerate the development of our AI-powered precision medicine SaMD,” stated François Cadiou.
Using sensor technologies and machine learning, Healint generates real-world evidence to improve treatment outcomes. Aptar Digital leverages a holistic ecosystem of digital interventions to empower patients and create a positive treatment journey.
